Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Author:
Funder
Università degli Studi di Perugia
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Internal Medicine
Link
https://link.springer.com/content/pdf/10.1007/s40292-022-00529-2.pdf
Reference53 articles.
1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72. https://doi.org/10.1093/eurheartj/ehx144.
2. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004;160(5):421–9. https://doi.org/10.1093/aje/kwh237.
3. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (Lond, Engl). 2010;376(9753):1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5.
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434–44. https://doi.org/10.2337/diacare.16.2.434.
5. Visseren F, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs F, Hollander M, Jankowska EA, ESC Scientific Document Group et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prevent Cardiol 2022;29(1):5–115. https://doi.org/10.1093/eurjpc/zwab154.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cardiovascular risk assessment in Portugal's primary health care system: SCORE vs. SCORE2;Revista Portuguesa de Cardiologia;2024-08
2. The Dynamics of Cardiovascular Risk—An Analysis of the Prospective Urban Rural Epidemiology (PURE) Poland Cohort Study;Journal of Clinical Medicine;2024-06-26
3. Atherosclerotic cardiovascular disease landscape in Singapore;Frontiers in Cardiovascular Medicine;2024-04-24
4. Effects of 12 Weeks of Continuous Exercise and Accumulation of Short-Duration Exercise on Body Composition, Physical Fitness, and Lifestyle Disease indices in Overweight Men in their 30s;Korean Journal of Sport Science;2023-09-30
5. Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy;Cancers;2022-07-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3